Anthem Biosciences Announces Audited Financial Results for FY26 and Q4FY26
Bengaluru, May 19, 2026: Anthem Biosciences Limited, an innovation-driven and technology-focused Contract Research, Development and Manufacturing Organization (CRDMO), announced its Audited Consolidated Financial Results for the quarter and year ended March 31, 2026.The financial highlights show significant growth across key metrics for the fiscal year 2025-2026 (FY26) and the fourth quarter (Q4FY26).
Q4FY26 and FY26 Financial Performance
The company's performance metrics across key periods are detailed in the following table:| Particulars (₹ Mn) | Q4FY26 | Q4FY25 | YoY | Q3FY26 | QoQ | FY26 | FY25 | YoY |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 6,109 | 4,832 | 26.4% | 4,232 | 44.4% | 21,243 | 18,446 | 15.2% |
| CRDMO | 5,128 | 3,923 | 30.7% | 3,332 | 53.9% | 17,727 | 15,061 | 17.7% |
| Specialty Ingredients | 981 | 909 | 7.9% | 899 | 9.1% | 3,516 | 3,385 | 3.9% |
| Other Income | 512 | 140 | 265.7% | 335 | 52.8% | 1,558 | 857 | 81.8% |
| Total Revenues | 6,622 | 4,973 | 33.2% | 4,567 | 45.0% | 22,801 | 19,303 | 18.1% |
| EBITDA | 3,184 | 2,092 | 52.2% | 1,907 | 66.9% | 9,896 | 7,566 | 30.8% |
| Profit before tax before exceptional items | 2,769 | 1,783 | 55.3% | 1,558 | 77.8% | 8,486 | 6,569 | 29.2% |
| Exceptional Items - impact of new labour code | (10) | n.a. | n.a. | 254 | n.a. | 244 | n.a | n.a. |
| Profit before tax after exceptional items | 2,779 | 1,783 | 55.9% | 1,305 | 112.9% | 8,242 | 6,569 | 25.5% |
| Profit after tax | 1,898 | 826 | 129.8% | 928 | 104.5% | 5,918 | 4,513 | 31.1% |
Financial Highlights Summary
For the Year Ended March 31, 2026:The consolidated Revenue from Operations for the full year stood at ₹21,243 Mn. The CRDMO business segment generated ₹17,727 Mn in revenues, while Specialty Ingredients contributed ₹3,516 Mn. EBITDA reached ₹9,896 Mn, achieving an EBITDA margin of 43.4%. Total revenues benefited from Other Income of ₹1,558 Mn (up from ₹857 Mn in FY25). Profit After Tax (PAT) for the year was ₹5,918 Mn, yielding PAT margins of 26.0%. The net cash position as of March 31, 2026, is ₹13,743 Mn.
For the Quarter Ended March 31, 2026:
Consolidated Revenue from Operations for the quarter was ₹6,109 Mn. The CRDMO segment accounted for ₹5,128 Mn of the revenue, and Specialty Ingredients recorded ₹981 Mn. EBITDA for Q4FY26 stood at ₹3,184 Mn, demonstrating an EBITDA margin of 48.1%. PAT for the quarter was ₹1,898 Mn, with PAT margins at 28.7%.
The Profit Before Tax (PBT) before exceptions items for the full year was ₹8,486 Mn, with the recorded exceptional item related to the new labor code impact amounting to ₹244 Mn.
Management Commentary
Commenting on the results, Ajay Bhardwaj, Chairman, MD and CEO, Anthem Biosciences Limited, noted that the company concluded the financial year 2025-26 on a strong note, achieving its highest revenue quarter ever in Q4FY26.Bhardwaj stated, "We delivered a Revenue growth of 26% Year over Year (YoY) for the quarter and 15% YoY for the financial year 2025-26. Anthem's commitment to prudent cost management and focus on long-term value creation has enabled us to expand profitability margins while delivering this revenue growth. Our EBITDA and PAT for the year grew by more than 30% in line with our growth aspirations."
The CEO added that the company continues to maintain a healthy financial position and is committed to delivering sustainable growth. For the financial year 2026-27, the focus remains on building one of the most agile, science-led, and future-ready CRDMO platforms in the world.
ANTHEM Stock Price Movement
On Tuesday, Anthem Biosciences Limited shares shed 1.12%, settling at ₹787.35 for the session. The stock saw a total traded volume of 293,810 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: